All In Biotech

Free tool

FAERS Monitor: Zituvimet

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 216743 or its brand name (Zituvimet, Metformin Hydrochloride, Sitagliptin). Reports on generic versions are filed under their own applications.

Reports

40

Serious

26

65% of reports

Hospitalization

10

Death reported

4

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective6
  • completed suicide4
  • dizziness4
  • pain in extremity4
  • abnormal dreams3
  • diarrhoea3
  • malaise3
  • nausea3
  • somnolence3
  • anxiety2
  • blood bilirubin increased2
  • blood creatinine increased2
  • blood glucose increased2
  • decreased appetite2
  • gamma-glutamyltransferase increased2

Reports by year received

View as table
YearReports
20103
201113
201221
20251
20262

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,119 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
abnormal dreamsSignal357.119.2114
gamma-glutamyltransferase increased247.512.350
blood bilirubin increased238.910.141
completed suicideSignal425.210.071
blood creatinine increased216.14.215
somnolenceSignal37.82.612
pain in extremitySignal47.12.816
blood glucose increased25.61.44
decreased appetite24.51.23
dizzinessSignal44.21.77
anxiety23.71.02
malaise33.61.23
diarrhoea32.40.81
drug ineffective62.41.14
nausea32.00.71

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.